Professor Adam Brufsky discusses NALA

NALA was a multi-national, randomised, open-label Phase 3 trial of NERLYNX (neratinib)/capecitabine versus lapatinib/capecitabine in patients with HER2+ mBC who had received more than 2 prior lines of HER2-directed therapy.  Investigators found that the NERLYNX/capecitabine cohort had significantly improved PFS and importantly, there was a significant delay in the onset and progression of brain metastases in the NERLYNX treated patients.

Abstract link: https://abstracts.asco.org/239/AbstView_239_262265.html

Watch the interview by clicking the link below.